Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
All-oral ivosidenib + sonrotoclax + chidamide for newly diagnosed IDH1-mutated acute myeloid leukemia
ChiCTR2600131633Phase 2Not yet recruiting
- Sponsor
- First Affiliated Hospital, Zhejiang University School of Medicine
- Start
- Sep 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of ivosidenib, sonrotoclax and tucidinostat in acute myeloid leukemia (AML) (3 cohorts), sponsored by First Affiliated Hospital, Zhejiang University School of Medicine. Primary endpoint: 1-year event-free survival rate. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
ivosidenibsonrotoclaxtucidinostat
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on ChiCTR2600131633.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600131633.